Add Adicet Bio Inc. to the long and growing list of private biotechnology firms raising venture capital in January, proving that the industry is able to attract investors despite declining stock values for publicly traded drug development companies.
Menlo Park, California-based Adicet raised $51m in a Series A round to fund development of off-the-shelf cell therapies for cancer...


![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

